RFA-OD-22-019: Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Cohort Study Sites for Pediatric Follow Up. Clinical Trial Not Allowed (UG3/UH3)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 21, 2022.
From the official notice on Grants.gov, last changed August 30, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG3 / UH3
- Clinical trialsNot allowed
- Funded byOD
- Median yearly award$1.1 million
- Typical project length8.5 years
- UG3, Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Other open UG3 notices.
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under RFA-OD-22-019 were run by NIH Office of the Director (OD, 32 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-OD-22-019 in the NIH Guide.
Key dates
| Posted | August 30, 2022 |
|---|---|
| Deadline | November 21, 2022 |
| Archived by Grants.gov | December 27, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the money in the 20 programs behind this notice (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This funding opportunity announcement (FOA) invites applications to renew current ECHO Cohort Study Sites to extend the capacity of the ECHO Cohort to further investigate the roles of a broad range of early exposures from society to biology on ECHOs five key child health outcome areaspre-, peri- and postnatal, upper and lower airways, obesity, neurodevelopment, and positive healthamong diverse populations. The objectives of this FOA are to solicit applications to 1) lead collaborative ECHO Cohort science, 2) follow up existing ECHO Cohort participants, and 3) implement the ECHO Cohort Data and Biospecimen Collection Protocol using the ECHO Cohort consortiums central data capture system, e.g., REDCap Central. This FOA does not support site-specific analyses and science. Only current ECHO Cohort awardees are eligible to apply. This new funding period will be 7 years in duration provided successful performance in the UG3 phase and the UH3 phase. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites for a limited competition of follow-up of existing ECHO Cohort participants AND of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA ZZZZ), for ECHO Cohort Study Sites only for an open competition of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA YYYY), for an ECHO Coordinating Center (RFANNNN), for an ECHO Data Analysis Center (RFA NNNN), for an ECHO Measurement Core (RFA NNNN), and for an ECHO Laboratory Core (RFA NNNN).
Funded under RFA-OD-22-019 so far
NIH funded 32 projects under RFA-OD-22-019 in fiscal 2023 to 2026, at 16 institutions. The median yearly award was $1.1 million.
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Other programs behind this notice
- Diabetes, Digestive, and Kidney Diseases Extramural Research
- Extramural Research Programs in the Neurosciences and Neurological Disorders
- Mental Health Research Grants
- Drug Use and Addiction Research Programs
- Child Health and Human Development Extramural Research
- Trans-NIH Research Support
- National Center for Advancing Translational Sciences
- Alcohol Research Programs
- Environmental Health
- Minority Health and Health Disparities Research
- Oral Diseases and Disorders Research
- Cancer Control
- Nursing Research
- Research and Training in Complementary and Integrative Health
- Medical Library Assistance
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-OD-22-019 still open?
No. It closed on November 21, 2022.
Who can apply for Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Cohort Study Sites for Pediatric Follow Up. Clinical Trial Not Allowed (UG3/UH3)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: Environmental influences on Child Health Outcomes (ECHO) Cohort Study Sites for Pediatric Follow Up. Clinical Trial Not Allowed (UG3/UH3)?
Closed November 21, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-OD-22-019?
NIH RePORTER lists 32 projects funded under RFA-OD-22-019 in fiscal 2023 to 2026, at 16 institutions. The most were at University of Colorado Denver, University of California at Davis, Univ of North Carolina Chapel Hill.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)